OR WAIT 15 SECS
Juniper Pharma Services has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles.
Juniper Pharma Services, formerly known as Molecular Profiles, has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles. These injectable particles, which when used in conjunction with new generation ultrasound devices, can be applied to a range of therapeutic applications including an oncological drug delivery platform called SonoTran. SonoTran is designed to enhance the delivery of anti-cancer drugs deep into and throughout solid tumors.
Colin Story, CEO of OxSonics, said in a press release that this technology has potential to deliver a step-change in the performance of drugs for solid tumors. The company is working with Juniper Pharma Services to take the development of its proprietary sono-sensitive particles from a laboratory-scale to clinical trial-scale and grade.
According to Story, OxSonics’ main objective is to commercialize the SonoTran platform, which has the capability to overcome one of the challenges facing solid tumor cancer therapy by delivering drugs throughout tumor volumes including to those areas that lie farthest from blood vessels. Under this agreement, Juniper Pharma Services will manufacture the technology for clinical studies on behalf of OxSonics
Source: Juniper Pharmaceuticals